JPM26: BioNTech gears up for multiproduct oncology status by 2030
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines.…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership
Eli Lilly and NVIDIA will establish a new artificial intelligence (AI) co-innovation lab, as the companies look to use each…
-
Podcast: Healthcare’s biggest 2025 trends and 2026 predictions
As the healthcare industry embarks on a new year, there are several factors that look set to impact pharmaceutical and…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its…
-
FDA unveils new pathway to usher bespoke therapies to market
The US Food and Drug Administration (FDA) has created a new pathway to bring personalised therapies to market that can…
-
FDA’s revolving door reveals Pazdur as new CDER head
The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking…
-
Europe looks east for clinical trial growth amid continent’s wider freeze
Amid the growing role of China in the clinical trial space and dominant investment role the US continues to play,…
-
Proactive strategy needed to ensure Project Optimus compliance
Sponsors should ensure dose optimisation is a part of early trial planning for oncology trials as the US Food and…